Literature DB >> 21163180

National surveillance of pandemic influenza A(H1N1) infection-related admissions to intensive care units during the 2009-10 winter peak in Denmark: two complementary approaches.

S Gubbels1, A Perner, P Valentiner-Branth, K Molbak.   

Abstract

Surveillance of 2009 pandemic influenza A(H1N1) in Denmark was enhanced during the 2009–10 winter season with a system monitoring the burden of the pandemic on intensive care units (ICUs), in order to inform policymakers and detect shortages in ICUs in a timely manner. Between week 46 of 2009 and week 11 of 2010, all 36 relevant Danish ICUs reported in two ways: aggregate data were reported online and case-based data on paper. Cases to be reported were defined as patients admitted to an ICU with laboratory-confirmed 2009 pandemic influenza A(H1N1) infection or clinically suspected illness after close contact with a laboratory-confirmed case. Aggregate numbers of cases were reported weekly: during weeks 48-51 (the peak), reporting was daily. The case-based reports contained demographic and clinical information. The aggregate surveillance registered 93 new cases, the case-based surveillance 61, of whom 53 were laboratory confirmed. The proportion of beds used for influenza patients did not exceed 4.5% of the national capacity. Hospitals with cases used a median of 11% of bed capacity (range: 3–40%). Of the patients for whom information was available, 15 of 48 patients developed renal insufficiency, 19 of 50 developed septic shock and 17 of 53 died. The number of patients with pandemic influenza could be managed within the national bed capacity, although the impact on some ICUs was substantial. The combination of both reporting methods (collecting aggregate and case-based data) proved to be useful for monitoring the burden of the pandemic on ICUs.

Entities:  

Mesh:

Year:  2010        PMID: 21163180     DOI: 10.2807/ese.15.49.19743-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  6 in total

1.  Long-term respiratory follow-up of H1N1 infection.

Authors:  Paul Zarogoulidis; George Kouliatsis; Nikolaos Papanas; Dionysis Spyratos; Theodoros C Constantinidis; Ioannis Kouroumichakis; Paschalis Steiropoulos; Maria Mabroudi; Dimitris Matthaios; Theodora Kerenidi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis; Efstratios Maltezos
Journal:  Virol J       Date:  2011-06-25       Impact factor: 4.099

2.  Health costs from hospitalization with H1N1 infection during the 2009-2010 influenza pandemic compared with non-H1N1 respiratory infections.

Authors:  Paul Zarogoulidis; Dimitrios Glaros; Theodoros Kontakiotis; Marios Froudarakis; Ioannis Kioumis; Ioannis Kouroumichakis; Anastasios Tsiotsios; Anastasios Kallianos; Paschalis Steiropoulos; Konstantinos Porpodis; Evagelia Nena; Despoina Papakosta; Aggeliki Rapti; Theodoros C Constantinidis; Theodora Kerenidi; Maria Panopoulou; Georgia Trakada; Nikolaos Courcoutsakis; Evangelia Fouka; Konstantinos Zarogoulidis; Efstratios Maltezos
Journal:  Int J Gen Med       Date:  2012-03-05

3.  Burden and characteristics of influenza A and B in Danish intensive care units during the 2009/10 and 2010/11 influenza seasons.

Authors:  S Gubbels; T G Krause; K Bragstad; A Perner; K Mølbak; S Glismann
Journal:  Epidemiol Infect       Date:  2012-07-16       Impact factor: 4.434

4.  Public hygiene campaign in denmark during the 2009 H1N1 pandemic had no effect on hospitalization rate of communicable diseases in children.

Authors:  Nadja Hawwa Vissing; Astrid Sevelsted; Hans Bisgaard
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

5.  The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations.

Authors:  Iben Ørsted; Mette Mølvadgaard; Hans Linde Nielsen; Henrik Nielsen
Journal:  Influenza Other Respir Viruses       Date:  2013-02-09       Impact factor: 4.380

Review 6.  SARS-CoV-2 epidemiology and control, different scenarios for Turkey

Authors:  Eskild Petersen; Deniz Gökengin
Journal:  Turk J Med Sci       Date:  2020-04-21       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.